The National Consumer Disputes Redressal Commission (NCDRC) has directed a Rajasthan-based hospital and its ENT specialist to ...

The National Consumer Disputes Redressal Commission (NCDRC) has directed a Rajasthan-based hospital and its ENT specialist to ...

Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path ...

Congestion - that bunged up, stuffy nose ­feeling - is usually a fleeting symptom of a cold which lasts for around a week and ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

The national consumer disputes redressal commission (NCDRC) has upheld the Rajasthan state consumer commission’s finding of ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

A Thai woman condemned a private hospital in the central province of Samut Sakhon after treatment for nasal polyps left her boyfriend blind.

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

THOUSAND OAKS (dpa-AFX) - AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire (tezepelumab) has received European Union approval as an add-on therapy with intranasal corticosteroids for ...

Tezspire (tezepelumab-ekko) is a prescription medicine used to treat inflammatory conditions of the airways, such as severe asthma. The FDA has now approved it as an add-on treatment for adults and ...